Key result
Pharmaceutical care significantly reduces SBP and DBP vs control in hypertension.
Why the study?
The effect of pharmaceutical care programs on blood pressure control in individuals with hypertension was evaluated due to uncertainty about their efficacy.
Do pharmaceutical care programs improve blood pressure control in individuals with hypertension?
Meta-Analysis (n=585)
Do pharmaceutical care programs improve blood pressure control in individuals with hypertension?
Pharmaceutical care programs are an effective tool for improving blood pressure control in hypertensive patients.
Pharmaceutical care programs aid BP control in hypertension; confirms RCT benefits and supports pharmacist integration into routine care.
Objective: To evaluate the effect of pharmaceutical care (PC) programs on blood pressure control in individuals with hypertension. Methods: Studies were retrieved by searching MEDLINE, EMBASE, Cochrane, CNKI, and CBM databases from 1999 to February 2008. Randomized controlled trials (RCTs) on the association of pharmaceutical care programs with blood pressure control in individuals with hypertension were included in this study. Moreover, the studies were selected independently by 2 authors. The analysis was conducted by using Review Manager version 4.2 software. Results: Five RCTs with a total of 585 patients with hypertension were included in this meta-analysis. Compared with the control group, the PC program intervention group had significantly lower endpoint systolic blood pressure (SBP) and diastolic blood pressure (DBP). Moreover, SBP and DBP were significantly improved in the intervention group relative to the control group. Conclusions: PC programs appear to be an effective tool in helping to control blood pressure in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2009) conducted a meta-analysis in hypertension (n=585). Pharmaceutical care programs vs. control group was evaluated on endpoint systolic blood pressure (SBP) and diastolic blood pressure (DBP). Pharmaceutical care programs significantly lowered endpoint systolic and diastolic blood pressure compared with the control group in patients with hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: